Early data highlight potential of venetoclax–azacitidine in relapsed or refractory MDS

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Jun 14 / Springer Healthcare

Early data highlight potential of venetoclax–azacitidine in relapsed or refractory MDS

Yale University and Yale Cancer Center, New Haven, Connecticut, USA

Haematology EHA-2020

Description

Amer Zeidan discusses phase 1b trial findings demonstrating promising efficacy and manageable tolerability of venetoclax plus azacitidine in patients with relapsed or refractory myelodysplastic syndrome.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.